Welcome to Moleculera Biosciences

Medical resources for healthcare providers

We are committed to helping healthcare providers improve clinical outcomes for patients with treatment resistant neuropsychiatric symptoms through innovative autoantibody testing with the Autoimmune Brain Panel™.

Autoimmune Brain Panel™

Giving you insights to improve patient care.

Our clinically validated Panel includes 5 assays. Four tests measure the levels of circulating autoantibodies in serum that are directed against neuronal targets: Dopamine D1 and D2 receptors, Lysoganglioside and Tubulin. The fifth test, the CaMKII, is a cell stimulation assay. This test measures the ability of the patient’s autoantibodies to stimulate the CaMKII enzyme that is responsible for the upregulation of brain neurotransmitters.

Elevated levels indicate that a patient’s neurologic and/or psychiatric symptoms may be due to a treatable autoimmune dysfunction.

Autoimmune Brain Panel™ Sensitivity and Specificity

Is This Right For Your Patients?

Insights to help guide treatment.

Our goal is to assist clinicians in identifying an underlying autoimmune etiology in patients presenting with difficult to treat neuropsychiatric symptoms. Studies indicate that for a subset of patients, neurologic and/or psychiatric manifestations may actually be due to a treatable autoimmune dysfunction, rather than a primary neurologic or psychiatric disorder.

These patients typically do not respond to or have had an adverse reaction to standard medications, have a personal or family history of autoimmune disorders, and a preceding infection. Patients may experience a sudden onset of symptoms, including OCD-like behaviors, tics, major depressive disorder or seizures.

neuropsychiatric disorders - young woman
Patient with neuropsychiatric disorders
Patient with neuropsychiatric symptoms

Is This Right For Your Patients?

Innovative science that impacts lives.

Our goal is to assist clinicians in identifying an underlying autoimmune etiology in patients presenting with difficult to treat neuropsychiatric symptoms. Studies indicate that for a subset of patients, neurologic and/or psychiatric manifestations may actually be due to a treatable autoimmune dysfunction, rather than a primary neurologic or psychiatric disorder.

These patients typically do not respond to or have had an adverse reaction to standard medications, have a personal or family history of autoimmune disorders, and a preceding infection. Patients may experience a sudden onset of symptoms, including OCD-like behaviors, tics, major depressive disorder or seizures.

The Science behind the Autoimmune Brain Panel™

Common infections can trigger the immune system to produce autoantibodies which mistakenly attack healthy tissue in the basal ganglia region of the brain. This can disrupt normal neuronal cell signaling and cause inflammation in the brain, resulting in the onset of neurologic and/or psychiatric symptoms.
The Autoimmune Brain Panel™ measures the levels of circulating autoantibodies directed against the targets shown below which are associated with various neurologic and/or psychiatric symptoms.

Anti-Dopamine D1 Receptor

Associated with "psychiatric" symptoms; tends to correlate with mood instability, anxiety, irritability, aggression and, in some cases, psychosis.

Anti-Dopamine D2L Receptor

Associated with "movement" symptoms; tends to correlate with choreiform movements, mycolonus, and exacerbations of hyperactivity.

Anti-Lysoganglioside-GM1

Associated with tics; tends to correlate with complaints of joint or connective tissue pain.

Anti-Tubulin

Assciated with OCD, cognitive interference and "brain fog".

CaMKII – a Cell Stimulation Assay

Associated with sympathetic nervous system activation symptoms; fight or flight behavior, separation anxiety, urinary problems, bedwetting, sensory sensitivites.

Results you can count on.

In studies comparing pre- and post-treatment patient symptom status, findings revealed that the Autoimmune Brain Panel™ (also known as the Cunningham Panel™) results paralleled changes in a patient’s neuropsychiatric symptoms following treatment.
88%
SENSITIVITY
(Rate of true positives)
83%
SPECIFICITY
(Rate of true negatives)
86%
ACCURACY

What your colleagues are saying

The Autoimmune Brain Panel™ has been utilized by more than 2,500 healthcare providers worldwide with over 16,000 patients tested. Listen to leading clinicians discuss how they’ve utilized the Panel to improve patient outcomes.
Dr. Richard Horowitz

Hudson Valley Healing Arts Center

The Panel is fortunately a great tool for doctors to look at these antineuronal antibodies to find out who may be a candidate for IVIG.
Dr. Tania Dempsey

AIM CENTER FOR PERSONALIZED MEDICINE

I think the Panel is useful [at] really being able to look at the immune response that’s happening in the nervous system.
Dr. Daniel Kinderlehrer

INTERNIST

The Panel has a lot of utility in evaluating these patients in whom the etiology of their neuropsychiatric disorder is not clear.
Personalized consultation and easy to use portal
We’re here to help you better understand the Autoimmune Brain Panel™ and how it can benefit your patients. Sign up for a free consultation to discuss whether the Panel may be right for a particular patient or to review test results.
Talk to an expert about the Autoimmune Brain Panel

Talk To An Expert

Personalized Consultations about the Autoimmune Brain Panel™. Talk to us.

How To Order The Panel

Open a Provider Account to order the panel and access patient results.

Educational Resources

We have compiled educational materials, including case reports and published studies on the Autoimmune Brain Panel™ (also known as the Cunningham Panel™), that may be helpful as you treat patients with infection-triggered autoimmune neuropsychiatric disorders.